Human Antibody Broadly Protects Against Hantavirus Infection

Read our paper in Science Translational Medicine describing our work on the isolation of human monoclonal antibodies against the glycoprotein spikes of rodent-borne hantaviruses associated with severe human disease in Northern Europe. Our investigations led us to a single antibody that is a promising candidate for clinical development as a broad countermeasure against hantaviruses. The way this antibody binds to the hantavirus spike also informs the development of broadly protective hantavirus vaccines.

This work was the product of our NIH-funded international consortium, Prometheus, whose goal is to to develop antibody-based therapies against hantaviruses and other highly lethal viruses for which there are no approved vaccines or treatments.

Co-led by Eva Mittler in the lab (Team).

Learn more about the implications of our findings here.

See this New York Times story for more on Prometheus and watch a video about the Prometheus team.